Angiotensin‐converting enzyme inhibitors showed no clear difference in death (any cause) compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Angiotensin‐converting enzyme inhibitors showed no clear difference in CVD events: total (fatal and non‐fatal) compared with placebo (low certainty).
Angiotensin‐converting enzyme inhibitors may leads to higher adverse events: number reporting an adverse event compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Angiotensin‐converting enzyme inhibitors (ACEi) probably leads to lower anuria compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in mortality compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (fatal) compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (non fatal) compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ treated with an… compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ not treated with an… compared with conventional therapy (moderate certainty).
Angiotensin‐converting‐enzyme inhibitors showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes cardiovascular death Median compared with placebo or no treatment (very low certainty).
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes doubling of SCr Median compared with placebo or no treatment (very low certainty).